The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.
FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
December 27, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022